Modern Chinese Medicine Group Co (HKSE:01643) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01643 Modern Chinese Medicine Group Co Ltd HKSE:01643
53 GF Score
Price HK$0.94
GF Value HK$0.16
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Modern Chinese Medicine Group Co FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:01643
53GF Score
Modern Chinese Medicine Group Co Ltd HKSE:01643
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Modern Chinese Medicine Group Co (HKSE:01643) Overvalued in 2026?

Based on GuruFocus' analysis, Modern Chinese Medicine Group Co stock appears to be overvalued. The current stock price of HK$0.94 is trading 487.5% above its estimated GF Value™ of HK$0.16. GuruFocus considers Modern Chinese Medicine Group Co to be Significantly Overvalued.

Key valuation signals for HKSE:01643:

  • FFO:
  • GF Value™: HK$0.16 vs. price of HK$0.94 (487.5% above fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the HKSE:01643 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Modern Chinese Medicine Group Co Business Description

Address No. 88 Jinwei Road, Hebei Province, Longhua County, Chengde, CHN, 068150
Modern Chinese Medicine Group Co Ltd is engaged in the production of Proprietary Chinese Medicines. It offers both OTC and prescribed medicines intended for use by the Middle-aged and the Elderly in the PRC. Its products include liver protection tablets, Shanmei capsules, Qi and blood supplement pills, and Xiaohuoluo pills, among others. Geographically, the company derives its key revenue from the People's Republic of China.
53GF Score

Get the complete analysis for HKSE:01643

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.94
Price
HK$0.16
GF Value